Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE (TM) Trial
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE (TM) Trial
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2020
Συγγραφείς:
Trotman, Judith Buske, Christian Tedeschi, Alessandra Matous, Jeffrey V MacDonald, David Tam, Constantine Tournilhac, Olivier Ma, Shuo Treon, Steven P Oriol, Albert others
